secwatch / observer
8-K filed January 31, 2023, 6:59 PM ET ticker CENT CIK 0000887733
earnings confidence high sentiment negative materiality 0.70

Central Garden & Pet Q1 net sales down 5% to $628M; posts $0.16 loss per share; maintains FY EPS outlook $2.60-$2.80

CENTRAL GARDEN & PET CO

2023-Q1 EPS reported -$0.16 revenue$627,663,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CENTRAL GARDEN & PET CO reported first quarter fiscal 2023 ended December 24, 2022 results: revenue $628 million, net income $8 million, EPS $0.16. Guidance reaffirmed.

Period
first quarter fiscal 2023 ended December 24, 2022
Revenue
$628 million
Net income
$8 million
EPS
$0.16
Guidance
reaffirmed
Result
reported results
Exact text from the filing
Net sales were $628 million compared to $661 million a year ago, a decline of 5%. Gross margin was 27.4% compared to 30.0% a year ago. The decline was driven primarily by the Garden segment largely due to cost inflation and unfavorable overhead absorption due to lower sales, partially offset by pricing actions. Operating income was $0.4 million compared to $26 million a year ago, and operating margin was 0.1% compared to 4.0% in the prior year. The operating margin decline was primarily driven by the Garden segment largely due to cost inflation and overhead absorption pressures from lower sales, partially offset by lower commercial spend. Net interest expense of $14 million was in line with the prior year quarter. The Company's net loss was $8 million compared to net income of $9 million a year ago. Loss per share was $0.16 compared to earnings per share of $0.16 in the prior year quarter.
View on SEC.gov

Browse all earnings releases →

CENTRAL GARDEN & PET CO filing history →

Source: SEC EDGAR
accession 0001157523-23-000131
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.